At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
BIA 2-093 +2 moredrug
Likely dose
BIA 2-093 900 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine Following Oral Administration in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating BIA 2-093, S-licarbazepine, and 1 other intervention for Epilepsy. Completed, enrolled 32 participants across 1 site.
Detailed Summary
Single centre, open-label, randomised study in four parallel groups of healthy volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
Primary CompletionJul 2006
First PostedNov 2014
TodayJul 2026
First PostedNov 3, 2014
Enrollment StartJun 1, 2006
Primary CompletionJul 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.7 years ago
Interventions
BIA 2-093drug
Tablets containing 900 mg
S-licarbazepinedrug
capsules containing 225 mg
R-licarbazepinedrug
capsules containing 225 mg